SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- InflammaGen Therapeutics, a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of Multiple Organ Failure (MOF), announced today that John Rodenrys, will present at Biotech Showcase 2012 in conjunction with the J.P. Morgan Healthcare Conference in San Francisco, CA. Mr. Rodenrys’ presentation will take place at the Parc 55 Wyndham on Monday, January 9, 2012 at 4:15 p.m. PST.
John Rodenrys, CEO of InflammaGen Therapeutics, remarked, “We welcome the opportunity to present Biotech Showcase 2012 to highlight the value of InflammaGen Shok-Pak as a potential treatment for shock and MOF. Despite the prevalence and severity of MOF, current therapies to treat this grave condition are limited both in availability and effectiveness.”
Hank Loy, president of InflammaGen Therapeutics, added, “Our therapeutic and diagnostic platform is being developed to address this severe medical need, with pre-clinical research and patient experiences demonstrating a remarkable ability to reverse shock and MOF, thereby enabling those inflicted with the condition to recover and survive.”
InflammaGen Shok-Pak is a drug/delivery technology designed to prevent the onset of shock and MOF via the direct administration of an enzyme inhibitor into the stomach and lumen of the intestine. InflammaGen Therapeutics is preparing to initiate a Phase 2 Pilot Study to evaluate the potential of InflammaGen Shok-Pak to reduce morbidity in hospitalized critically ill patients.
About InflammaGen Therapeutics
InflammaGen Therapeutics is a development-stage, critical care company initially focused on the diagnosis, treatment and prevention of Multiple Organ Failure (MOF), a condition with a high mortality rate and very few therapeutic options. The Company’s lead technology is InflammaGen Shok-Pak, a drug/delivery platform designed to prevent the onset of shock and MOF via the direct administration of an enzyme inhibitor into the stomach and lumen of the intestine. InflammaGen Shok-Pak was developed based on research from the University of California San Diego, which demonstrated that under conditions of shock, digestive enzymes permeate the wall of the intestine and enter the bloodstream, leading to multi-organ failure and death. Complementing InflammaGen Shok-Pak, the Company has also developed a diagnostic assay, AnaZyme, that uses either breath or blood samples to measure the presence and severity of inflammatory activity due to shock, and InflammaGen Lavage, a therapeutic for use in open wounds and areas of infection. InflammaGen Therapeutics is a Leading Biosciences’ company. For additional information on Leading Biosciences, please visit http://leadingbiosciences.com/. For additional information on InflammaGen Therapeutics or its MOF treatment platform, please visit http://igenrx.com/.
Contact Information:
Hank Loy
President
InflammaGen Therapeutics
949-939-6005
hank.loy@igenrx.com
Media Contacts:
Tiberend Strategic Advisors, Inc.
212-827-0020
Jason Rando / Stephanie Denis
jrando@tiberend.com / sdenis@tiberend.com
SOURCE InflammaGen Therapeutics
